2024-512510-17-00招募中1 期
A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Grünenthal Trial Information Desk
Scientific
Gruenenthal GmbH
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A randomized, single-center, double-blind, placebo-controlled, 2-way cross-over, single oral administration trial to evaluate blood-borne biomarker candidates to predict NOP receptor activation using GRT6010 as NOP receptor agonist in healthy human subjects.neuropathic pain10034606NL-OMON37607Grunenthal24
进行中（未招募）
不适用
A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformiEUCTR2006-001219-31-DEovartis Pharma Services AG22
进行中（未招募）
不适用
A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 diabetesType II DiabetesEUCTR2006-001218-34-SEovartis Pharma Services AG28
尚未招募
Unknown
A single-center, double-blind, randomized, placebo-controlled clinical study of Shuhe granule in the treatment of chronic insomnia with qi-blood disharmony and deficiency of both heart and kidneyinsomniaITMCTR2024000035Guangdong Provincial Hospitai of Chinese Medicine
已完成
不适用
A single-center, double-blind, randomized, placebo-controlled Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-1014-6470 in healthy subjects, including food effect, mass balance, and metabolite profilinginflammatory diseasesNL-OMON48421Idorsia Pharmaceuticals Ltd88